Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2025-12-26 @ 3:11 AM
Study NCT ID:
NCT03556020
Status:
TERMINATED
Last Update Posted:
2022-08-23
First Post:
2018-06-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
Sponsor:
PhaseBio Pharmaceuticals Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-07-15
Start Date Type:
ACTUAL
Primary Completion Date:
2022-01-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-01-07
Completion Date Type:
ACTUAL
First Submit Date:
2018-06-01
First Submit QC Date:
None
Study First Post Date:
2018-06-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2022-08-23
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2022-08-18
Last Update Post Date:
2022-08-23
Last Update Post Date Type:
ACTUAL